Clinical trials: MG - Myasthenia Gravis
Myasthenia Gravis, Neuromuscular Disease
Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment
This study expands and validates the pilot study NCT06381284. It is a fully remote, site-less, prospective, observational study enrolling adults in the United States (excluding U.S.
- Conditions
- Myasthenia Gravis, Neuromuscular Disease, Neuromuscular Manifestations
- Trial name
- NCT06866483
- Testing
- Social media recruitment, Self-Assessment, Follow-up
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ZS Associates
Myasthenia Gravis
Physical Activity Monitoring in Myasthenia Gravis
The goal of this observational study is to evaluate the feasibility of using wearable sensor and digital technologies to measure motor and speech function in adults with autoimmune Myasthenia Gravis (MG).
- Trial name
- NCT06277830
- Testing
- Wearable sensor
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Myasthenia Gravis, Pharmacokinetics
A Single-Center, Randomized, Open-Label, Two-Sequence, Two-Period, Crossover Study Comparing the Pharmacokinetics and Safety of Pyridostigmine Sustained-Release and Immediate-Release Tablets Following Single and Multiple Doses in Healthy Chinese Participants
This study aimed to assess the pharmacokinetic profile, safety, and tolerability of a new sustained-release pyridostigmine tablet versus the reference product.
- Trial name
- NCT07154095
- Testing
- Sustained-Release Tablets, Immediate-Release Tablets
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- West China Second University Hospital
Myasthenia Gravis
Pyridostigmine and Amifampridine for Myasthenia Gravis
A randomized, double-blind, placebo controlled, crossover intervention study evaluating the effect of pyridostigmine (part 1) and amifampridine (part 2) in Myasthenia Gravis (MG).
- Trial name
- IMPACT-MG (NCT05919407)
- Testing
- Pyridostigmine, Amifampridine (base) with modified release
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Leiden University Medical Center
Myasthenia Gravis
Translation, Cross-cultural Adaptation and Validation of the MGQOL-15-F
The purpose of this study is to translate and culturally adapt the MGQOL-15 (health-related quality of life scale for myasthenia gravis) for use with French-speaking patients in France and to evaluate its psychometric properties…
- Trial name
- MGQOL-15-F (NCT02470364)
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Predictor, Myasthenia Gravis
Predictors of Myasthenia Gravis Outcome Following Thoracoscopic Thymectomy: Comparative Study Between Thymomatous and Non-Thymomatous Patients
This study aimed to assess and compare predictors of outcome in patients with thymomatous and non-thymomatous MG undergoing Thoracoscopic thymectomy.
- Conditions
- Predictor, Myasthenia Gravis, Thoracoscopic Thymectomy, Thymomatous
- Trial name
- NCT07319689
- Testing
- Data collection
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Tanta University
Generalized Myasthenia Gravis (gMG), Refractory gMG
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG
This is an open-label, single-arm, multi-center study to evaluate the efficacy, safety, PK, PD, and immunogenicity of eculizumab in Chinese participants with refractory gMG.
- Trial name
- ECU-MG-304 (NCT06764160)
- Testing
- Eculizumab
- Where
- 6 sites in China
- Volunteers
- 15 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Generalized Myasthenia Gravis
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with generalized myasthenia gravis.
- Trial name
- NCT06447597
- Testing
- B007
- Where
- 18 sites in China
- Volunteers
- 104 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
Myasthenia Gravis
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of IM-101 in adult participants with AChR antibody-positive gMG.
- Trial name
- Synergy-MG (NCT07250750)
- Testing
- IM-101 Part A, IM-101 Part B
- Where
- 25 sites in United States, Bulgaria and 4 more
- Volunteers
- 96 people
- Sponsor
- ImmunAbs Inc.
Myasthenia Gravis (MG), Myasthenia Gravis, Generalized
AXIS MG Patient Registry
The goal of the AXIS Autoimmune Neurology Registry is to learn about the experiences of adults living with autoimmune neurological disorders, starting with myasthenia gravis (MG), over time.
- Conditions
- Myasthenia Gravis (MG), Myasthenia Gravis, Generalized, Myasthenia Gravis, Ocular, Myasthenia Gravis Crisis
- Trial name
- AXIS (NCT07761026)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Autoimmune Neurology Alliance
Myasthenia Gravis
Clinical Prognosis and Progression of Myasthenia Gravis Patients
This study collects the clinical data of myasthenia gravis (MG) patients, assesses outcomes and adverse effects of different treatment regimens, and searches for risk factors of conversion to generalized MG.
- Trial name
- NCT04101578
- Testing
- Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Da, Yuwei, M.D.
Myasthenia Gravis, Generalized
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis
- Trial name
- NCT04146051
- Testing
- Descartes-08
- Where
- 15 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Cartesian Therapeutics
Myasthaenia Gravis, Myasthenia
Myasthenia Gravis Foundation of America Global MG Patient Registry
The goal of this observational study is to learn about the experiences of people living with Myasthenia Gravis (MG) in the United States.
- Conditions
- Myasthaenia Gravis, Myasthenia, Myasthenia Gravis Associated with Thymoma, Myasthenia Gravis Crisis
- Trial name
- MGFAPR (NCT06617741)
- Where
- United States
- Volunteers
- 3,800 people
- Sponsor
- Myasthenia Gravis Foundation of America
Myasthenia Gravis
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis…
- Trial name
- NCT03863080
- Testing
- RVT-1401
- Where
- 20 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- Immunovant Sciences GmbH
Generalized Myasthenia Gravis
Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis
This randomized controlled, multi-center study will carry out to assess the efficacy of GB-0998 compared to plasmapheresis in the treatment of the generalized Myasthenia Gravis based on the changes in Quantitative Myasthenia…
- Trial name
- NCT00515450
- Testing
- GB-0998 (Intravenous immunoglobulin), Plasmapheresis
- Where
- Japan
- Volunteers
- 46 people
- Sponsor
- Benesis Corporation
Myasthenia Gravis, Myasthenic Syndrome
Patient Observation With Environmental and Wearable Sensors in Myasthenia Gravis
This observational study seeks to investigate the underlying processes of myasthenia gravis by employing multimodal monitoring techniques.
- Conditions
- Myasthenia Gravis, Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome
- Trial name
- POWER-MG (NCT06441825)
- Testing
- Increased multimodal observation including digital monitoring
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Ocular Myasthenia Gravis
Ocular Mysathenia Gravis Generalization
Secondary ocular myasthenia gravis (OMG) generalization represents a pejorative evolution and no validated generalization prevention strategy exists.
- Trial name
- MYASTEN (NCT04667650)
- Testing
- Use of nomogram for predictions of Ocular Mysathenia Gravis generalization
- Where
- France
- Volunteers
- 151 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Myasthenia Gravis
Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) as a corticosteroid (CS)-sparing agent in…
- Trial name
- NCT02473965
- Testing
- IGIV-C
- Where
- 39 sites in United States, Belgium and 8 more
- Volunteers
- 60 people
- Sponsor
- Grifols Therapeutics LLC
Reversal of Neuromuscular Blockade
Efficacy and Safety of Sugammadex in Thoracoscopy Thymectomy for Chinese Adults With Myasthenia Gravis
The purpose of this study was to demonstrate in patients with myasthenia gravis (MG) undergoing thoracoscopic thymectomy faster recovery from a moderate neuromuscular block induced by rocuronium after reversal at reappearance of…
- Trial name
- NCT06436768
- Testing
- Sugammadex, Neostigmine
- Where
- 2 sites in China
- Volunteers
- 62 people
- Sponsor
- Beijing Tongren Hospital
SCAD, Addison Disease
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
This case control study aims to determine whether spontaneous coronary artery dissection (SCAD) is associated with autoimmune diseases and to update the incidence of SCAD in a population-based cohort.
- Conditions
- SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome
- Trial name
- NCT03941184
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Mayo Clinic